Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Unknown × NSCLC × Clear all

Phase

Phase 2 12 Phase 4 5 Phase 2/3 5 Phase 3 3 Phase NA 2 Phase 1/2 1 Phase 1 1

Status

Recruiting 3 Withdrawn 2 Unknown 1 Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 68 Carcinoma, Non-Small-Cell Lung 64 Breast Neoplasms 60 Recurrence 59 Carcinoma, Hepatocellular 54 Colorectal Neoplasms 50 Multiple Myeloma 48 Melanoma 47 Pancreatic Neoplasms 46 Leukemia, Myeloid, Acute 45 Neoplasm Metastasis 43 Lymphoma 43 Advanced Solid Tumors 42 Advanced Solid Tumor 40 Precursor Cell Lymphoblastic Leukemia-Lymphoma 38 Stomach Neoplasms 37 Solid Tumor 33 Glioblastoma 33 Ovarian Neoplasms 32 Lymphoma, B-Cell 31 Prostatic Neoplasms 30 Lung Neoplasms 30 Lymphoma, Non-Hodgkin 27 Leukemia 25 Uterine Cervical Neoplasms 23 Leukemia, Lymphocytic, Chronic, B-Cell 22 Esophageal Neoplasms 22 Burkitt Lymphoma 22 Head and Neck Neoplasms 20 Colonic Neoplasms 17

Interventions

apatinib 1 Gefitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡